CAR T-Cell Therapy for Glioblastoma

Glioblastoma is the most formidable of primary brain tumors, owing to its aggressive nature and the limited efficacy of the best available treatment, which comprises maximal safe surgical resection, radiotherapy, and alkylating chemotherapy. Most patients die within a year after diagnosis, which underscores the urgent need for innovative therapeutic strategies. Of interest, then, is an interim analysis in this issue of the Journal: Choi et al.1 report the outcomes of treating three patients with a secreting chimeric antigen receptor (CAR) T cell (see Key Concepts). CAR T-cell technology has reshaped our therapeutic approach to combating hematologic cancers. It harnesses the . . .